1-8 of 8
Zhi Xiang Shen, MD
Close
Sort by
Journal Articles

Frontline Nilotinib Results In Superior Rates Of Molecular Response Versus Imatinib In Chinese Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP): ENESTchina 12-Month Primary Analysis

Xiaojun Huang, Jianxiang Wang, MD, Michele Baccarani, MD, Svetlana Jevtic, Christine-Elke Ortmann, Ye Yuan, Hans D. Menssen, MD, PhD, Giuseppe Saglio, Zhi-Xiang Shen, MD
Journal: Blood
Blood (2013) 122 (21): 1497.
https://doi.org/10.1182/blood.V122.21.1497.1497
Published: 2013
Journal Articles

Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study

Jong Wook Lee, MD, PhD, Sung-Soo Yoon, MD, PhD, Zhi Xiang Shen, MD, Arnold Ganser, MD, Hui-Chi Hsu, MD, Ali El-Ali, MD, Dany Habr, MD, Bernard Roubert, PhD, John B. Porter, MD, on behalf of the EPIC study investigators
Journal: Blood
Blood (2011) 118 (21): 1344.
https://doi.org/10.1182/blood.V118.21.1344.1344
Published: 2011
Journal Articles

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Bing Chen, Xiang Wang, Ying Yao, Yong-Mei Zhu, Hai-Yan He, Xiao-Xing Jiang, Ji-Fang Zhou, Hai-Min Chen, Qi Cao, Guang Yang, Chun-Lei Jiang, Xiang-Qin Weng, Xu-Xi Zhang, Bo Jiao, Wei Li Zhao, MD, PhD, Jun-Min Li, Yu Chen, Shu-Min Xiong, Zhi-Xiang Shen, MD, Long-Jun Gu, MD, Hui Jiang, Jian-Qing Mi, Zhu Chen, Sai-Juan Chen, PhD
Journal: Blood
Blood (2009) 114 (22): 4718.
https://doi.org/10.1182/blood.V114.22.4718.4718
Published: 2009
Journal Articles

Long-Term Outcome of Imatinib Treatment in Chronic Myeloid Leukemia (CML) Patients in Shanghai: An International Patient Assistance Programs (GIPAP) Analysis.

Ai-hua Wang, Li Zhou, Yu Zheng, Jun-min Li, Zhi-Xiang Shen, MD, Jiong Hu, MD
Journal: Blood
Blood (2009) 114 (22): 4275.
https://doi.org/10.1182/blood.V114.22.4275.4275
Published: 2009
Journal Articles

Efficacy and Safety of Bosutinib (SKI-606) in Patients with Chronic Phase (CP) Ph+ Chronic Myelogenous Leukemia (CML) with Resistance or Intolerance to Imatinib.

Jorge Cortes, MD, Hagop M Kantarjian, Dong- Wook Kim, MD, PhD, H. Jean Khoury, MD, FACP, Anna G. Turkina, MD, Zhi-Xiang Shen, MD, Tim H Brummendorf, MD, Mammen Chandy, MD, Steven Arkin, MD, Carlo Gambacorti-Passerini, MD
Journal: Blood
Blood (2008) 112 (11): 1098.
https://doi.org/10.1182/blood.V112.11.1098.1098
Published: 2008
Journal Articles

A Retrospective Study of Introferon-Alpha Treatment on Chinese Patients with Chronic Myeloid Leukemia

Hua Yan, Zhi-Xiang Shen, MD
Journal: Blood
Blood (2008) 112 (11): 4287.
https://doi.org/10.1182/blood.V112.11.4287.4287
Published: 2008
Journal Articles

A Multicentre, Randomized Study of FLAG Treatment in China(CHORT).

Hua Yan, Zhi-Xiang Shen, MD, Jianxiang Wang
Journal: Blood
Blood (2008) 112 (11): 948.
https://doi.org/10.1182/blood.V112.11.948.948
Published: 2008
Journal Articles

Bortezomib (Velcade™) Observational Study in China - Efficacy and Safety of Bortezomib Based Regimen in 223 Relapsed or Refractory Multiple Myeloma Patients.

Zhi-xiang Shen, MD
Journal: Blood
Blood (2007) 110 (11): 4833.
https://doi.org/10.1182/blood.V110.11.4833.4833
Published: 2007